{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:51:58Z","timestamp":1761918718758},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,5,3]],"date-time":"2005-05-03T00:00:00Z","timestamp":1115078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00262-005-0699-9","type":"journal-article","created":{"date-parts":[[2005,5,3]],"date-time":"2005-05-03T09:28:45Z","timestamp":1115112525000},"page":"1153-1161","source":"Crossref","is-referenced-by-count":68,"title":["Regulatory T cells and tumor immunity"],"prefix":"10.1007","volume":"54","author":[{"given":"Subhasis","family":"Chattopadhyay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitya G.","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijay","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,5,3]]},"reference":[{"key":"699_CR1","first-page":"723","volume":"18","author":"RK Gershon","year":"1970","unstructured":"Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723","journal-title":"Immunology"},{"key":"699_CR2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-3083.1988.tb02344.x","volume":"27","author":"G Moller","year":"1988","unstructured":"Moller G (1988) Do suppressor T cells exist? Scand J Immunol 27:247","journal-title":"Scand J Immunol"},{"key":"699_CR3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","volume":"22","author":"S Sakaguchi","year":"2004","unstructured":"Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531","journal-title":"Annu Rev Immunol"},{"key":"699_CR4","doi-asserted-by":"crossref","first-page":"F41","DOI":"10.1084\/jem.193.11.F41","volume":"193","author":"EM Shevach","year":"2001","unstructured":"Shevach EM (2001) Certified professionals: CD4+CD25+ suppressor T cells. J Exp Med 193:F41","journal-title":"J Exp Med"},{"key":"699_CR5","first-page":"156","volume":"156","author":"S Sakaguchi","year":"1982","unstructured":"Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: I. Requirement of Lyt-1 effector cells for oocyte damage after adoptive transfer. J Exp Med 156:156","journal-title":"J Exp Med"},{"key":"699_CR6","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.156.6.1577","volume":"156","author":"S Sakaguchi","year":"1982","unstructured":"Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: II. Requirement of Lyt-1 effector cells in normal female mice for the prevention of oophoritis. J Exp Med 156:1577","journal-title":"J Exp Med"},{"key":"699_CR7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1084\/jem.161.1.72","volume":"161","author":"S Sakaguchi","year":"1985","unstructured":"Sakaguchi S, Fukuma K, Kuribiashi K, Masuda T (1985) Organ specific autoimmunie diseases induced in mice by elimination of T cell subsets. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a subset as possible cause of autoimmunity. J Exp Med 161:72","journal-title":"J Exp Med"},{"key":"699_CR8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor a-chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151","journal-title":"J Immunol"},{"key":"699_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1084\/jem.151.1.69","volume":"151","author":"MJ Berendt","year":"1980","unstructured":"Berendt MJ, North RJ (1980) T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69","journal-title":"J Exp Med"},{"key":"699_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(08)60265-1","volume":"45","author":"RJ North","year":"1985","unstructured":"North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1","journal-title":"Adv Cancer Res"},{"key":"699_CR11","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.4049\/jimmunol.136.5.1888","volume":"136","author":"B Mukherji","year":"1986","unstructured":"Mukherji B, Wilhelm SA, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136:1888","journal-title":"J Immunol"},{"key":"699_CR12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.4049\/jimmunol.136.5.1893","volume":"136","author":"B Mukherji","year":"1986","unstructured":"Mukherji B, Nashed AL, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136:1893","journal-title":"J Immunol"},{"key":"699_CR13","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1084\/jem.169.6.1961","volume":"169","author":"B Mukherji","year":"1989","unstructured":"Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961","journal-title":"J Exp Med"},{"key":"699_CR14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","volume":"26","author":"S Sakaguchi","year":"2000","unstructured":"Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 26:455","journal-title":"Cell"},{"key":"699_CR15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1034\/j.1600-065X.2001.1820102.x","volume":"182","author":"S Sakaguchi","year":"2001","unstructured":"Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki Y, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahasi T (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18","journal-title":"Immunol Rev"},{"key":"699_CR16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.smim.2003.12.003","volume":"16","author":"CA Piccirillo","year":"2004","unstructured":"Piccirillo CA, Shevach EM (2004) Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 16:81","journal-title":"Semin Immunol"},{"key":"699_CR17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm0804-801","volume":"10","author":"A O\u2019Garra","year":"2004","unstructured":"O\u2019Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nature Med 10:801","journal-title":"Nat Med"},{"key":"699_CR18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.coph.2004.05.001","volume":"4","author":"C Thompson","year":"2004","unstructured":"Thompson C, Powrie F (2004) Regulatory T cells. Curr Opin Pharmacol 4:408","journal-title":"Curr Opin Pharmacol"},{"key":"699_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nri1026","volume":"3","author":"JF Bach","year":"2003","unstructured":"Bach JF (2003) Regulatory T cells under scrutiny. Nature Rev Immunol 3:189","journal-title":"Nature Rev Immunol"},{"key":"699_CR20","first-page":"273","volume":"5","author":"P Ehrlich","year":"1909","unstructured":"Ehrlich P (1909) Nederlandsch Tijdschrift voor Geneeskunde: Ueber den jetzigne Stand Der Karzinomforchung. Weekblad Jaargang Eerst helft 5:273","journal-title":"Weekblad Jaargang Eerst helft"},{"key":"699_CR21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0167-5699(88)91269-8","volume":"9","author":"PK Srivastava","year":"1988","unstructured":"Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9:78","journal-title":"Immunol Today"},{"key":"699_CR22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.183.3.725","volume":"183","author":"T Boon","year":"1996","unstructured":"Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725","journal-title":"J Exp Med"},{"key":"699_CR23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-5699(97)84664-6","volume":"18","author":"SA Rosenberg","year":"1997","unstructured":"Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175","journal-title":"Immunol Today"},{"key":"699_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00262-004-0560-6","volume":"54","author":"L Novellino","year":"2005","unstructured":"Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 54:187","journal-title":"Cancer Immunol Immunother"},{"key":"699_CR25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1359","volume":"4","author":"E Gilboa","year":"2004","unstructured":"Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4:401","journal-title":"Nat Rev Cancer"},{"key":"699_CR26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329","journal-title":"Annu Rev Immunol"},{"key":"699_CR27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","volume":"74","author":"FM Marincola","year":"2000","unstructured":"Marincola FM, Jaffee EM, Hiclin DJ, Ferrone S (2000) Escape of human solid tumors from T cell-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181","journal-title":"Adv Immunol"},{"key":"699_CR28","first-page":"843","volume":"53","author":"Pawlec","year":"2004","unstructured":"Pawlec (2004) Tumor escape from the immune response. Cancer Immunol Immunother 53:843","journal-title":"Cancer Immunol Immunother"},{"key":"699_CR29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00262-004-0540-x","volume":"53","author":"M Ahmad","year":"2004","unstructured":"Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy; possible mechanisms that influence tumor regression\/progression. Cancer Immunol Immunother 53:844","journal-title":"Cancer Immunol Immunother"},{"key":"699_CR30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00262-004-0526-8","volume":"53","author":"A Anichini","year":"2004","unstructured":"Anichini A, Vigetti C, Mortini R (2004) The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855","journal-title":"Cancer Immunol Immunother"},{"key":"699_CR31","first-page":"865","volume":"53","author":"TL Whiteside","year":"2004","unstructured":"Whiteside TL (2004) Down-regulation of the z-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865","journal-title":"Cancer Immunol Immunother"},{"key":"699_CR32","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.4049\/jimmunol.162.9.5576","volume":"162","author":"NG Chakraborty","year":"1999","unstructured":"Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) Emergence of Th2 type CD4+ T cell response to repetitive stimulation with antigen and antigen presenting cells, in vitro: Implications in designing tumor vaccines. J Immunol 162:5576","journal-title":"J Immunol"},{"key":"699_CR33","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.4049\/jimmunol.138.6.1987","volume":"138","author":"B Mukherji","year":"1987","unstructured":"Mukherji B, Guha A, Loomis R, Ergin MT (1987) Cell-mediated amplification and down-regulation of cytotoxic immune response against autologous human cancer. J Immunol 138:1987","journal-title":"J Immunol"},{"key":"699_CR34","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.4049\/jimmunol.145.7.2359","volume":"145","author":"NG Chakraborty","year":"1990","unstructured":"Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytolytic response. J Immunol 145:2359","journal-title":"J Immunol"},{"key":"699_CR35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-065X.1990.tb00803.x","volume":"116","author":"B Mukherji","year":"1990","unstructured":"Mukherji B, Chakraborty NG, Sivanandham M (1990) T cell clones that react against human tumors. Immunol Rev 116:33","journal-title":"Immunol Rev"},{"key":"699_CR36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/39614","volume":"389","author":"H Groux","year":"1997","unstructured":"Groux H, O\u2019Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T cell subset inhibits antigen specific T cell responses and prevents colitis. Nature 389:737","journal-title":"Nature"},{"key":"699_CR37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-065X.2001.1820105.x","volume":"182","author":"MG Roncarolo","year":"2001","unstructured":"Roncarolo MG, Bachetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68","journal-title":"Immunol Rev"},{"key":"699_CR38","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.humimm.2004.05.012","volume":"65","author":"NG Chakraborty","year":"2004","unstructured":"Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T cells response and tumor vaccine induced CTL in human melanoma. Human Immunol 65:794","journal-title":"Hum Immunol"},{"key":"699_CR39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(03)00359-5","volume":"20","author":"HY Wang","year":"2004","unstructured":"Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor specific human CD4+ regulatory T cells and their ligands: implications for immunottherapy. Immunity 20:107","journal-title":"Immunity"},{"key":"699_CR40","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"S ShimizuJ. Yamazaki","year":"1999","unstructured":"Shimizu J. Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211","journal-title":"J Immunol"},{"key":"699_CR41","first-page":"3128","volume":"59","author":"S Onizuka","year":"1999","unstructured":"Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukine-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128","journal-title":"Cancer Res"},{"key":"699_CR42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2567.2002.01471.x","volume":"107","author":"A Gallimore","year":"2002","unstructured":"Gallimore A, Sakaguchi S (2002) Regulation of tumor immunity by CD25+ T cells. Immunology 107:5","journal-title":"Immunology"},{"key":"699_CR43","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1084\/jem.194.6.823","volume":"194","author":"RP Sutmuller","year":"2001","unstructured":"Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocytes-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J Exp Med 194:823","journal-title":"J Exp Med"},{"key":"699_CR44","first-page":"1","volume":"2","author":"E Jones","year":"2002","unstructured":"Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol 2:1","journal-title":"Cancer Immunol"},{"key":"699_CR45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00262-003-0444-1","volume":"53","author":"W Wei-Zen","year":"2004","unstructured":"Wei-Zen W, Morris GP, Kong Yi-chi M (2004) Antitumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73","journal-title":"Cancer Immunol Immunother"},{"key":"699_CR46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00002371-200205000-00003","volume":"25","author":"H Tanaka","year":"2002","unstructured":"Tanaka H, Tanaka J, Jorgen K, Shu S (2002) Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207","journal-title":"J Immunolther"},{"key":"699_CR47","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1002\/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1","volume":"32","author":"D Golgher","year":"2002","unstructured":"Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine rejection antigens. Eur J Immunol 32:3267","journal-title":"Eur J Immunol"},{"key":"699_CR48","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.168.9.4272","volume":"168","author":"EY Woo","year":"2002","unstructured":"Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients inhibit autologous T cell proliferation. J Immunol 168:4272","journal-title":"J Immunol"},{"key":"699_CR49","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","volume":"34","author":"F Ghiringhelli","year":"2004","unstructured":"Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+D25+ regulatory T cells suppress tumor immunity sensitive to cyclophosphamide which allows immunotherapy in established tumors to be curative. Eur J Immunol 34:336","journal-title":"Eur J Immunol"},{"key":"699_CR50","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.4049\/jimmunol.171.11.5931","volume":"171","author":"N Casares","year":"2003","unstructured":"Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+\/CD25+ regulatory cells inhibit activation of tumor primed CD4+ T cells with IFN-\u03b3-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931","journal-title":"J Immunol"},{"key":"699_CR51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.20041130","volume":"20","author":"MJ Turk","year":"2004","unstructured":"Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 20:771","journal-title":"J Exp Med"},{"key":"699_CR52","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo HG, Tanaka Y, Hermann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756","journal-title":"J Immunol"},{"key":"699_CR53","first-page":"5267","volume":"62","author":"R Somasundaram","year":"2002","unstructured":"Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+\/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267","journal-title":"Cancer Res"},{"key":"699_CR54","first-page":"606","volume":"9","author":"AM Wolf","year":"2003","unstructured":"Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606","journal-title":"Clin Cancer Res"},{"key":"699_CR55","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","volume":"103","author":"NA Marshall","year":"2003","unstructured":"Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2003) Immunosuppressive regulatory T cells ate abundant in tumor lymphocytes of Hodgkins lymphoma. Blood 103:1755","journal-title":"Blood"},{"key":"699_CR56","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00002371-200301000-00009","volume":"26","author":"LR Javia","year":"2003","unstructured":"Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85","journal-title":"J Immunother"},{"key":"699_CR57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.coi.2004.01.010","volume":"16","author":"M Terabe","year":"2004","unstructured":"Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:167","journal-title":"Curr Opin Immunol"},{"key":"699_CR58","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942","journal-title":"Nat Med"},{"key":"699_CR59","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","volume":"173","author":"M Viguier","year":"2004","unstructured":"Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+CD25+ regulatory T cells are overexpressed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444","journal-title":"J Immunol"},{"key":"699_CR60","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.4049\/jimmunol.171.11.5678","volume":"171","author":"C Cozzo III","year":"2003","unstructured":"Cozzo C, Larkin J III, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 171:5678","journal-title":"J Immunol"},{"key":"699_CR61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.188.2.287","volume":"188","author":"AM Thronton","year":"1998","unstructured":"Thronton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287","journal-title":"J Exp Med"},{"key":"699_CR62","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.4049\/jimmunol.162.9.5317","volume":"162","author":"M Itoh","year":"1999","unstructured":"Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: Production of CD25+CD4+ Naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317","journal-title":"J Immunol"},{"key":"699_CR63","doi-asserted-by":"crossref","first-page":"6210","DOI":"10.4049\/jimmunol.169.11.6210","volume":"169","author":"C Baecher-Allan","year":"2002","unstructured":"Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD(+)CD25(+high) regulatory T cell function. J Immunol 169:6210","journal-title":"J Immunol"},{"key":"699_CR64","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2004-01-0086","volume":"104","author":"P Hoffmann","year":"2004","unstructured":"Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger R (2004) Large-scale in vitro expansion of polyclonal human CD4(+) CD25high regulatory T cells. Blood 104:895","journal-title":"Blood"},{"key":"699_CR65","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/eji.200324455","volume":"24","author":"AM Thronton","year":"2004","unstructured":"Thronton AM, Picirillo CA, Shevach EM (2004) Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 24:366","journal-title":"Eur J Immunol"},{"key":"699_CR66","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.4049\/jimmunol.172.11.6519","volume":"172","author":"AM Thornton","year":"2004","unstructured":"Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519","journal-title":"J Immunol"},{"key":"699_CR67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1189\/jlb.0603272","volume":"74","author":"TR Malek","year":"2003","unstructured":"Malek TR (2003) The main function of IL-2 is to promote the development of regulatory T cells. J Leukoc Biol 74:961","journal-title":"J Leukoc Biol"},{"key":"699_CR68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/jaut.2000.0473","volume":"16","author":"E Suri-Payer","year":"2001","unstructured":"Suri-Payer E, Cantor H (2001) Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+ T cells. J Autoimmun 16:115","journal-title":"J Autoimmun"},{"key":"699_CR69","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.190.7.995","volume":"190","author":"C Asseman","year":"1999","unstructured":"Asseman C, Mauze S, Leach M, Coffman Rl, Powrie F (1999) An essential role for interleukin-10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995","journal-title":"J Exp Med"},{"key":"699_CR70","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature01152","volume":"420","author":"Y Balkaid","year":"2002","unstructured":"Balkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sachs DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502","journal-title":"Nature"},{"key":"699_CR71","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","volume":"192","author":"T Takahashi","year":"2000","unstructured":"Takahashi T, Tagami T, Yamazuki S, Ueda T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Dominant immunologic self-tolerance by CD4+CD25+ regulatory T cells constitutively expressing CTLA-4. J Exp Med 192:303","journal-title":"J Exp Med"},{"key":"699_CR72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.192.2.295","volume":"192","author":"S Read","year":"2000","unstructured":"Read S, Maimstrom S, Powrie F (2000) CTLA-4 plays an essential role in the function of CD4+CD25+ regulatory cells which control intestinal inflammation. J Exp Med 192:295","journal-title":"J Exp Med"},{"key":"699_CR73","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1084\/jem.194.5.629","volume":"194","author":"K Nakamura","year":"2001","unstructured":"Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface bound transformation growth factor beta. J Exp Med 194:629","journal-title":"J Exp Med"},{"key":"699_CR74","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.20020110","volume":"196","author":"F Annunziato","year":"2002","unstructured":"Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S (2002) Phenotype localization and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 196:379","journal-title":"J Exp Med"},{"key":"699_CR75","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000067596","volume":"129","author":"MK Levings","year":"2002","unstructured":"Levings MK, Bacchetta R, Schulz U, Roncarolo MG (2002) The role of IL-10 and TGF beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 129:263","journal-title":"Int Arch Allergy Immunol"},{"key":"699_CR76","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4049\/jimmunol.167.3.1137","volume":"167","author":"CA Piccirillo","year":"2001","unstructured":"Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137","journal-title":"J Immunol"},{"key":"699_CR77","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X","volume":"30","author":"L Cederbom","year":"2000","unstructured":"Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30:1538","journal-title":"Eur J Immunol"},{"key":"699_CR78","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.4049\/jimmunol.172.8.4676","volume":"172","author":"N Misra","year":"2004","unstructured":"Misra N, Bayry J, Lacroix-demazes S, Kazatcchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676","journal-title":"J Immunol"},{"key":"699_CR79","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/ni908","volume":"4","author":"AV Gett","year":"2003","unstructured":"Gett AV, Sallusto F, Lanzavecchia A, Geginat J (2003) T cell fitness determined by signal strength. Nat Immunol 4:355","journal-title":"Nat Immunol"},{"key":"699_CR80","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.4049\/jimmunol.173.10.6017","volume":"173","author":"S Mehrotra","year":"2004","unstructured":"Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B (2004) Rescuing melanoma epitope specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunoterapy. J Immunol 173:6017","journal-title":"J Immunol"},{"key":"699_CR81","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","volume":"155","author":"RJ North","year":"1982","unstructured":"North RJ (1982) Cyclophosphamode-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063","journal-title":"J Exp Med"},{"key":"699_CR82","first-page":"90","volume":"71","author":"RJ North","year":"1990","unstructured":"North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90","journal-title":"Immunology"},{"key":"699_CR83","first-page":"1671","volume":"48","author":"D Berd","year":"1988","unstructured":"Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T -cells. Cancer Res 48:1671","journal-title":"Cancer Res"},{"key":"699_CR84","first-page":"3689","volume":"61","author":"J-P H Michiels","year":"2001","unstructured":"Michiels J-P H, Reilly RT, Emens LA, Ercollini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immmune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice. Cancer Res 61:3689","journal-title":"Cancer Res"},{"key":"699_CR85","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nri821","volume":"2","author":"EM Shevach","year":"2002","unstructured":"Shevach EM (2002) CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389","journal-title":"Nat Rev Immunol"},{"key":"699_CR86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cellimm.2004.02.004","volume":"227","author":"M Cohn","year":"2004","unstructured":"Cohn M (2004) Whither T-suppressors: if they did not exist would we have to invent them? Cell Immunol 227:81","journal-title":"Cell Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-005-0699-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0699-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T04:11:21Z","timestamp":1683087081000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-005-0699-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,3]]},"references-count":86,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1007\/s00262-005-0699-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,3]]}}}